Celularity (Celularity) Debt-to-Equity : 2.02 (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Celularity Debt-to-Equity?

Celularity's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $35.00 Mil. Celularity's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $26.07 Mil. Celularity's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $30.25 Mil. Celularity's debt to equity for the quarter that ended in Sep. 2023 was 2.02.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Celularity's Debt-to-Equity or its related term are showing as below:

CELU' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.06 Med: 0.33 Max: 2.02
Current: 2.02

During the past 3 years, the highest Debt-to-Equity Ratio of Celularity was 2.02. The lowest was -0.06. And the median was 0.33.

CELU's Debt-to-Equity is ranked worse than
95.02% of 1065 companies
in the Biotechnology industry
Industry Median: 0.14 vs CELU: 2.02

Celularity Debt-to-Equity Historical Data

The historical data trend for Celularity's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celularity Debt-to-Equity Chart

Celularity Annual Data

Trend

Dec20

Dec21

Dec22

Debt-to-Equity

-0.06

0.31

0.33

Celularity Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Debt-to-Equity	Get a 7-Day Free Trial									0.41	0.33	0.41	0.52	2.02

Competitive Comparison of Celularity's Debt-to-Equity

For the Biotechnology subindustry, Celularity's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Celularity's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celularity's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Celularity's Debt-to-Equity falls into.

Celularity Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Celularity's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(37.603	+	27.985)	/	198.901
	=	0.33

Celularity's Debt to Equity Ratio for the quarter that ended in Sep. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(35.004	+	26.074)	/	30.247
	=	2.02

Celularity (NAS:CELU) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Celularity Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Celularity's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Celularity (Celularity) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celularity Inc (NAS:CELU) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

170 Park Avenue, Florham Park, NJ, USA, 07932

Website

https://www.celularity.com

Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases.

Executives

Kok Thay Lim	director	22ND FLOOR, WISMA GENTING, JALAN SULTAN ISMAIL, KUALA LUMPUR N8 50250
Robert J Hariri	director, officer: Chief Executive Officer	341 MENDHAM ROAD, BERNARDSVILLE NJ 07924
Ling Geoffrey M.d.	director	C/O CATALYST BIOSCIENCES, INC., 611 GATEWAY BOULEVARD, SUITE 710, SOUTH SAN FRANCISCO CA 94080
Berhad Genting	10 percent owner	24TH FLOOR, WISMA GENTING, JALAN SULTAN ISMAIL, KUALA LUMPUR N8 50250
Adrian Kilcoyne	officer: See Remarks	533 AIRPORT BLVD., SUITE 400, BURLINGAME CA 94010
John Sculley	director	C/O KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVENUE, LEXINGTON MA 02421
Kyle Fletcher	officer: General Counsel	CELULARITY INC., 170 PARK AVE., FLORHAM PARK NJ 07932
Peter Diamandis	director	4640 ADMIRALTY WAY, SUITE 500, MARINA DEL REY CA 90292
Dean C Kehler	director	C/O TRIMARAN CAPITAL PARTNERS, 622 THIRD AVENUE, 35TH FLOOR, NEW YORK NY 10017
Robin L Smith	director	C/O PHASE III MEDICAL, INC., 330 SOUTH SERVICE ROAD, SUITE 120, MELVILLE NY 11747
Marc Mazur	director	31 WEST 52ND ST. 17TH FLOOR, NEW YORK NY 10019
Diane L. Parks	director	29 EMMONS DRIVE, SUITE B-10, PRINCETON NJ 08540
Bradley Glover	director, officer: Chief Technology Officer	C/O CELULARITY INC., 170 PARK AVENUE, FLORHAM PARK NJ 07932
Stephen Brigido	officer: Pres, Functional Regeneration	C/O CELULARITY INC., 170 PARK AVENUE, FLORHAM PARK NJ 07932
Anne Jones	director, officer: Chief Business Officer	C/O CELULARITY INC., 170 PARK AVENUE, FLORHAM PARK NJ 07932